 | Up a level |
Journal Article
Ferreri, Andres J. M., Cwynarski, Kate, Pulczynski, Elko, Ponzoni, Mourilio, Deckert, Martina, Politi, Letterio S., Torri, Valter 
ORCID: 0000-0001-9541-9354, Fox, Christopher P., La Rosee, Paul ORCID: 0000-0002-6758-7809, Schorb, Elisabeth, Ambrosetti, Achille, Roth, Alexander, Hemmoway, Claire, Ferrari, Angela ORCID: 0000-0002-9984-1146, Linton, Kim M., Ruda, Roberta, Binder, Mascha ORCID: 0000-0003-0663-3004, Pukrop, Tobias, Balzarotti, Monica, Fabbri, Alberto, Johnson, Peter, Gorlov, Jette Sonderskov, Hess, Georg, Panse, Jens, Pisani, Francesco, Tucci, Alessandra ORCID: 0000-0003-3052-7463, Stilgenbauer, Stephan, Hertenstein, Bernd, Keller, Ulrich, Krause, Stefan W., Levis, Alessandro, Schmoll, Hans J., Covalli, Franco, Finke, Jurgen, Reni, Michele ORCID: 0000-0002-6463-0293, Zucca, Emanuele ORCID: 0000-0002-5522-6109 and Illerhaus, Gerald
(2016).
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol., 3 (5).
S. E217 - 11.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2352-3026